-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

John C. Jacobs
President and Chief Executive Officer
John C. Jacobs joined Novavax as president and chief executive officer, and a member of the board of directors, in January 2023. He is a seasoned industry leader who has more than 25 years of commercial, operations, business and leadership experience across multiple therapeutic areas. Previously, Mr. Jacobs served as president and chief executive officer and a member of the board of directors at Harmony Biosciences from June 2018 to January 2023, and executive vice president and chief commercial officer from October 2017 to June 2018, leading the company through a successful IPO and taking its first product through FDA review, approval and commercialization. Prior to joining Harmony, Mr. Jacobs held leadership roles at Teva Pharmaceuticals beginning in 2014, including senior vice president and general manager of the Respiratory Business Unit, senior vice president of Commercial Operations in North America and general manager of Teva in Canada. Mr. Jacobs has also held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon, Wyeth and Pfizer. Mr. Jacobs has a proven track record in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations. He received bachelor’s degree in business from State University of New York College at Plattsburgh and a master of business administration from The State University of New York at Binghamton.